GLP-1 and GIP in Mounjaro: why two receptors change the picture

You've read that Mounjaro 'works differently', here's what that actually means

Most people researching weight-loss injections already know that GLP-1 receptor agonists exist. Medicines like semaglutide work along one hormonal pathway: GLP-1, released in the gut after eating, signals fullness to the brain and slows the rate at which the stomach empties. That mechanism is well established and genuinely effective.

Tirzepatide does all of that, and then activates a second receptor too. GIP, glucose-dependent insulinotropic polypeptide, is another incretin hormone, but it operates differently. It acts on fat cells to influence how the body stores and releases energy, and it has receptors in the brain's appetite-regulation centres. When both pathways fire together, the appetite-suppressing effect is greater than either produces on its own. That is not a marketing claim; it is the mechanism that NICE reviewed when it recommended tirzepatide for weight management in the UK.

Think of it this way: GLP-1 turns the volume down on hunger; GIP shifts the dial on how your body handles the energy it already holds. The interaction between the two receptors appears to amplify the overall effect, which is why the clinical trial results attracted so much attention from researchers and regulators alike. If you want a fuller picture of how Mounjaro fits into the GLP-1 treatment landscape, the GLP-1 and Mounjaro page is a useful place to start, and you can also read more about how the two hormones relate on the GLP-1 and GIP in tirzepatide page.

What SURMOUNT-1 actually found, and the honest context around those numbers

The pivotal SURMOUNT-1 trial randomised 2,539 adults with obesity (without type 2 diabetes) to tirzepatide or placebo over 72 weeks, alongside a reduced-calorie diet and increased activity. At the highest dose tested (15 mg), participants lost an average of around 20–21% of body weight, results that informed NICE's recommendation of tirzepatide (TA1026), published in December 2024.

Those numbers deserve honest framing. Trial participants received structured lifestyle support throughout, were carefully monitored, and the figures represent averages across a specific population, not a guaranteed individual outcome. Results vary. Some people lose considerably more; some less. The question of whether tirzepatide is right for you, at which starting dose, and alongside what lifestyle adjustments is exactly what a prescriber works through at consultation.

In the later SURMOUNT-5 head-to-head trial, tirzepatide produced greater average weight reduction than semaglutide 2.4 mg over 72 weeks in adults with obesity, a direct comparison that had not previously been available. The tirzepatide overview page covers both sets of trial data in more detail.

GIP and GLP-1 together: the eligibility and access picture in the UK

Because tirzepatide is a prescription-only medicine, access begins with a clinical assessment, whether that is through the NHS or a regulated private pharmacy like nume. For the NHS route, NICE TA1026 sets specific eligibility thresholds: adults with a BMI of 35 or above plus at least one weight-related condition qualify under current criteria, and the rollout is phased. Lower BMI thresholds apply for people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds. NHS waiting times vary considerably by area.

Private prescribing follows the licensed criteria in the medicine's SmPC: broadly, adults with a BMI of 30 or above, or 27 or above with a qualifying weight-related condition. A prescriber still assesses the whole clinical picture, BMI alone does not guarantee a prescription. If you are curious about what private treatment involves or want to understand cost context, the Mounjaro pricing page sets that out plainly.

Treatment starts at 2.5 mg. That first dose is there to let your system settle, not to produce significant weight loss immediately. Titration typically moves in four-weekly steps, guided by your prescriber. Mounjaro comes as a pre-filled KwikPen; most people keep theirs in the fridge door and inject once a week on the same day each week. The Mounjaro information page covers storage, injection sites and the titration schedule in full.

Side effects and what to watch for when two pathways are active

The side-effect profile of tirzepatide is broadly similar to that of GLP-1-only medicines: nausea, vomiting, diarrhoea, constipation, indigestion, burping, fatigue and headache are the most commonly reported, and they tend to be most noticeable after starting treatment or after a dose increase. For most people they ease within days to a couple of weeks as the body adjusts, and you can find a fuller explanation of why on the Mounjaro GLP page.

One signal to know: acute pancreatitis is a known but infrequent serious side effect of GLP-1 medicines generally, and the MHRA highlighted it in a Drug Safety Update in January 2026. Severe, persistent stomach pain (especially if it radiates toward the back) needs urgent medical attention, not a wait-and-see approach. Side effects and unusual symptoms can be reported directly to the MHRA via the Yellow Card scheme.

If you have questions about how your other medicines interact with tirzepatide, or about conditions in your history that might be relevant, those are exactly the conversations to have with a prescriber before starting. Our clinical team reviews every consultation personally.